[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355919-105":59,"doc-detail-355919-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","mta2-decoding-pathogenic-mechanisms-clinical-implications-and-therapeutic-frontiers-across-disease-landscapes","MTA2: Decoding pathogenic mechanisms, clinical implications and therapeutic frontiers across disease landscapes","","Metastasis-associated protein 2 (MTA2), a key metastasis-associated family transcriptional regulator, functions as a core component of the Mi-2/nucleosome remodeling and deacetylase (NuRD) complex. It drives diverse human diseases through epigenetic regulation and coordinated integration of multiple signaling pathways. The review consolidates molecular and structural characteristics of MTA2 and evaluates its functional mechanisms in oncological and non-oncological settings, emphasizing roles in metastasis, drug resistance, and tumor microenvironment remodeling. It also outlines clinical diagnostic and therapeutic target value, targeted intervention strategies, and advances in specific inhibitors and rapid intraoperative detection.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mta2-decoding-pathogenic-mechanisms-clinical-implications-and-therapeutic-frontiers-across-disease-landscapes/355919/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mta2-decoding-pathogenic-mechanisms-clinical-implications-and-therapeutic-frontiers-across-disease-landscapes/355919.png","ImageObject",300,407,{"name":92,"@type":93},"Franzy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-20","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is MTA2 and what complex does it belong to?","Question",{"text":113,"@type":114},"MTA2 is a metastasis-associated family transcriptional regulator and a core component of the Mi-2/nucleosome remodeling and deacetylase (NuRD) complex.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does MTA2 contribute to disease?",{"text":118,"@type":114},"MTA2 contributes through epigenetic regulation and by integrating multiple signaling pathways, with reported involvement in tumor metastasis, drug resistance, and tumor microenvironment remodeling.",{"name":120,"@type":111,"acceptedAnswer":121},"What clinical uses and therapeutic directions are discussed for MTA2?",{"text":122,"@type":114},"The review highlights MTA2 as a potential diagnostic marker and therapeutic target, describes targeted intervention strategies, and discusses development of highly specific inhibitors and rapid detection methods for intraoperative assessment.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},355919,1791429048,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},2336478945519,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","INTERNATIONAL JOURNAL OF MOLEcULAR MEdIcINE 58: 228, 2026  \nMTA2: Decoding pathogenic mechanisms, clinical implications and therapeutic frontiers across disease landscapes (Review)  \nHAO XIE 1* , LING cHEN2* , JING GOU3* , XUEHONG LONG4 , YA YANG5 , HAI HU6 , PING WU7 , QIBING YAN3 and YONGKANG WU2,8  \n1  \ndepartment of Radiology, West china Hospital Sichuan University Jintang Hospital, Jintang First People's Hospital, chengdu, 2  \nSichuan 610400, P.R. china; West china Hospital Sichuan University Jintang Hospital, Jintang First People's Hospital, chengdu, Sichuan 610400, P.R. china; 3department of Laboratory Medicine, West china Hospital Sichuan University Jintang Hospital, Jintang First People's Hospital, chengdu, Sichuan 610400, P.R. china; 4Hospital Infection Management department,  \nWest china Hospital Sichuan University Jintang Hospital, Jintang First People's Hospital, chengdu, Sichuan 610400, P.R. china; 5  \ndepartment of Ultrasound Medicine, West china Hospital Sichuan University Jintang Hospital, Jintang First People's Hospital,  \n6  \nchengdu, Sichuan 610400, P.R. china; Department of Radiology, Sichuan University Affiliated Chengdu Second People's Hospital, chengdu, Sichuan 610052, P.R. china; 7department of Radiology, The Traditional chinese Medicine Hospital of Longquanyi,  \n8  \nchengdu, Sichuan 610101, P.R. china; department of Laboratory Medicine, West china Hospital, Sichuan University, chengdu, Sichuan 610041, P.R. china  \nReceived January 20, 2026; Accepted June 9, 2026  \ndOI: 10.3892/ijmm.2026.5899  \nAbstract. Metastasis‑associated protein 2 (MTA2), a crucial member of the metastasis‑associated family of transcriptional regulators, serves as a core component ofthe Mi‑2/nucleosome remodeling and deacetylase complex. It contributes to diverse human diseases through epigenetic regulation and integration of multiple signaling pathways . This paper systematically  \nCorrespondence to: dr Qibing Yan, department of Laboratory Medicine, West china Hospital Sichuan University Jintang Hospital, Jintang First People's Hospital, 886 Jinguang Road, Zhao Town, Jintang county, chengdu, Sichuan 610400, P.R. china  \nE‑mail: [270817420@qq.com](270817420@qq.com)  \nProfessor Yongkang Wu, department of Laboratory Medicine, West china Hospital, Sichuan University, 37 Guoxue Lane, Wuhou, chengdu, Sichuan 610041, P.R. china  \nE‑mail: [vipwyk@163.com](vipwyk@163.com)  \n*contributed equally  \nAbbreviations: AIB1, amplified in breast cancer 1; BAH, bromo‑adjacent homology; BITc, benzyl isothiocyanate; ceRNA, competing endogenous RNA; ddR, dNA damage response; EMT, epithelial‑mesenchymal transition; EScc, esophageal squamous cell carcinoma; EZH2, enhancer of zeste homolog 2; FAK, focal adhesion kinase; FSHR, follicle‑stimulating hormone receptor; MMP, matrix metalloproteinase; MTA, metastasis‑associated; NuRd, nucleosome remodeling and deacetylase; PTZN, phosphatase and tensin homolog deleted on chromosome ten; ROcK, Rho associated coiled‑coil containing protein kinase; uPA, urokinase‑type plasminogen activator  \nKey words: metastasis associated protein 2, tumor metastasis, tumor progression  \nreviews the molecular and structural properties of MTA2 and investigates its functional mechanisms in both oncological and non‑oncological contexts, focusing on breast cancer, gastric cancer and hepatocellular carcinoma, emphasizing its biolog‑ ical roles in cancer metastasis, drug resistance and tumor microenvironment remodeling. Building on existing research, the review highlights the clinical significance of MTA2 as a potential diagnostic marker and therapeutic target in cancer and discusses targeted intervention strategies aimed at the MTA2‑related regulatory network. Finally, the development of highly specific inhibitors targeting MTA2 and the estab‑ lishment of rapid MTA2 detection techniques for real‑time intraoperative margin assessment will fully unlock the clinical potential of MTA2 .  \nContents  \n1. Introduction  \n2. Pathogenic mechanis","cbCaifcBFDy6VfEt","https://ap.wps.com/l/cbCaifcBFDy6VfEt","pdf",2668416,17,"English","# Contents\n## Introduction\n## Pathogenic mechanisms of MTA2\n## Clinical implications and therapeutic frontiers across disease landscapes of MTA2\n## Future applications, prospects and challenges of MTA2","[{\"question\":\"What is MTA2 and what complex does it belong to?\",\"answer\":\"MTA2 is a metastasis-associated family transcriptional regulator and a core component of the Mi-2/nucleosome remodeling and deacetylase (NuRD) complex.\"},{\"question\":\"How does MTA2 contribute to disease?\",\"answer\":\"MTA2 contributes through epigenetic regulation and by integrating multiple signaling pathways, with reported involvement in tumor metastasis, drug resistance, and tumor microenvironment remodeling.\"},{\"question\":\"What clinical uses and therapeutic directions are discussed for MTA2?\",\"answer\":\"The review highlights MTA2 as a potential diagnostic marker and therapeutic target, describes targeted intervention strategies, and discusses development of highly specific inhibitors and rapid detection methods for intraoperative assessment.\"}]","MTA2: Decoding pathogenic mechanisms, clinical implications and therapeutic frontiers across disease landscapes | PDF",1790121759,43,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/66931a693e5eb8c51a7f5bd4fadace0a.webp",983,1357,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/35d647b46e703aa326ce49b4bd8a7eac.webp",982,1356,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5fd40fec2004f541955a7e4fea1b42d4.webp",981,1354,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e17fd78ce46732679c442539185927c0.webp",980,1353]